Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India

Awadhesh Kumar Singh, Ritu Singh, Shashank R Joshi, Anoop Misra, Awadhesh Kumar Singh, Ritu Singh, Shashank R Joshi, Anoop Misra

Abstract

Background and aims: There are increasing case reports of rhino-orbital mucormycosis in people with coronavirus disease 2019 (COVID-19), especially from India. Diabetes mellitus (DM) is an independent risk factor for both severe COVID-19 and mucormycosis. We aim to conduct a systematic review of literature to find out the patient's characteristics having mucormycosis and COVID-19.

Methods: We searched the electronic database of PubMed and Google Scholar from inception until May 13, 2021 using keywords. We retrieved all the granular details of case reports/series of patients with mucormycosis, and COVID-19 reported world-wide. Subsequently we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, use of steroids and its outcome in people with COVID-19.

Results: Overall, 101 cases of mucormycosis in people with COVID-19 have been reported, of which 82 cases were from India and 19 from the rest of the world. Mucormycosis was predominantly seen in males (78.9%), both in people who were active (59.4%) or recovered (40.6%) from COVID-19. Pre-existing diabetes mellitus (DM) was present in 80% of cases, while concomitant diabetic ketoacidosis (DKA) was present in 14.9%. Corticosteroid intake for the treatment of COVID-19 was recorded in 76.3% of cases. Mucormycosis involving nose and sinuses (88.9%) was most common followed by rhino-orbital (56.7%). Mortality was noted in 30.7% of the cases.

Conclusion: An unholy trinity of diabetes, rampant use of corticosteroid in a background of COVID-19 appears to increase mucormycosis. All efforts should be made to maintain optimal glucose and only judicious use of corticosteroids in patients with COVID-19.

Keywords: COVID-19; Corticosteroids; Diabetes mellitus; Mucormycosis; Systematic review.

Conflict of interest statement

Declaration of competing interest We hereby declare that we have no conflict of interest, related to this article titled “Mucormycosis in COVID-19: A Systematic Review of Cases Reported Worldwide and in India”.

Copyright © 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Figures

Fig. 1
Fig. 1
Postulated interaction of diabetes, corticosteroid and COVID-19 with mucormycosis.

References

    1. Kubin C.J., McConville T.H., Dietz D., et al. Open Forum Infectious Diseases; 2021. Characterization of bacterial and fungal infections in hospitalized patients with COVID-19 and factors associated with healthcare-associated infections. ofab201.
    1. Song G., Liang G., Liu W. Fungal Co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia. 2020 Aug;185(4):599–606.
    1. Paltauf A. Mycosis mucorina. Virchows Arch Pathol Anat Physiol Klin Med. 1885;102:543–564.
    1. Baker R.D. Mucormycosis-a new disease? J Am Med Assoc. 1957;163:805–808.
    1. Eucker J., Sezer O., Graf B., Possinger K. Mucormycoses. Mycoses. 2001;44(7):253–260.
    1. Sugar A.M. In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases. fifth ed. Mandell G.L., Bennett J.E., Dolin R., editors. Churchill Livingstone; New York, USA: 2000.
    1. Skiada A., Pavleas I., Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an Update. J Fungi. 2020;6(4):265.
    1. Chander J., Kaur M., Singla N., et al. Mucormycosis: battle with the deadly enemy over a five-year period in India. J. Fungi. 2018;4(2):46. doi: 10.3390/jof4020046.
    1. Prakash H., Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5:26.
    1. International Diabetes Federation Idf diabetes atlas. 2019. Available online:
    1. Jeong W., Keighley C., Wolfe R., et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26–34.
    1. Lionakis M.S., Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828–1838.
    1. Hoang K., Abdo T., Reinersman J.M., Lu R., Higuita N.I.A. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep. 2020;29(1):22–24.
    1. Skiada A., Pagano L., Groll A., et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European confederation of medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867.
    1. Deutsch P.G., Whittaker J., Prasad S. Invasive and non-invasive fungal rhinosinusitis—a review and update of the evidence. Medicina. 2019;55:1–14.
    1. Maartens G., Wood M.J. The clinical presentation and diagnosis of invasive fungal infections. J Antimicrob Chemother. 1991;28(13–22):17–44.
    1. Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020 Sep 30;12(9) e10726.
    1. Garg D., Muthu V., Sehgal I.S., Ramachandran R., et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia. 2021 May;186(2):289–298.
    1. Maini A., Tomar G., Khanna D., Kini Y., Mehta H., Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021 May 4;82:105957.
    1. Saldanha M., Reddy R., Vincent M.J. Title of the article: paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg. 2021 Apr 22:1–4. doi: 10.1007/s12070-021-02574-0. [Online ahead of print]
    1. Revannavar S.M., PS S., Samaga L. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021 Apr 27;14(4) e241663.
    1. Sen M., Lahane S., Lahane T.P., et al. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol. 2021;69:244–252.
    1. Sarkar S., Gokhale T., Choudhury S.S., Deb A.K. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021 Apr;69(4):1002–1004.
    1. Mishra N., Mutya V.S.S., Thomas A., et al. A case series of invasive mucormycosis in patients with COVID-19 infection. Int J Otorhinolaryngol Head Neck Surg. 2021 May;7(5):867–870.
    1. Satish D., Joy D., Ross A., Balasubramanya Mucormycosis coinfection associated with global COVID-19: a case series from India. Int J Otorhinolaryngol Head Neck Surg. 2021 May;7(5):815–820.
    1. Moorthy A., Gaikwad R., Krishna S., et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg. 2021 Mar 6:1–8. doi: 10.1007/s12663-021-01532-1. [Online ahead of print]
    1. Sharma S., Grover M., Bhargava S., Samdani S., Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021 Apr 8:1–6. doi: 10.1017/S0022215121000992. [Online ahead of print]
    1. Hanley B., Naresh K.N., Roufosse C., et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020 Oct;1(6):e245–e253.
    1. Dallalzadeh L.O., Ozzello D.J., Liu C.Y., Kikkawa D.O., Korn B.S. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit. 2021 Mar 23:1–4. doi: 10.1080/01676830.2021.1903044. [Online ahead of print]
    1. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264. e5–264.e8, In press.
    1. Placik D.A., Taylor W.L., Wnuk N.M. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep. 2020 Nov;15(11):2378–2381.
    1. Mekonnen Z.K., Ashraf D.C., Jankowski T., et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthalmic Plast Reconstr Surg. 2021;37 e40–80.
    1. Alekesyev K., Didenko L., Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12(3):85–89.
    1. Johnson A.K., Ghazarian Z., Cendrowski K.D., Persichino J.G. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep. 2021 Jun;32:64–67.
    1. Kanwar A., Jordan A., Olewiler S., Wehberg K., Cortes M., Jackson B.R. A fatal case of Rhizopus azygosporus pneumonia following COVID-19. J Fungi (Basel) 2021 Feb 28;7(3):174.
    1. Khatri A., Chang K.M., Berlinrut I., Wallach Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - case report and review of literature. J Mycol Med. 2021 Apr 2;31(2):101125.
    1. Monte Junior E.S.D., Santos M.E.L.D., Ribeiro I.B., et al. Rare and fatal gastrointestinal mucormycosis (zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020 Nov;53(6):746–749.
    1. Pasero D., Sanna S., Liperi C., et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020:1–6.
    1. Bellanger A.P., Navellou J.C., Lepiller Q., et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis News. 2021 Jan 27 doi: 10.1016/j.idnow.2021.01.010. S2666-9919(21)00030-0. [Online ahead of print]
    1. Karimi-Galougahi M., Arastou S., Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19) Int Forum Allergy Rhinol. 2021 Mar 13 doi: 10.1002/alr.22785. [Online ahead of print]
    1. Veisi A., Bagheri A., Eshaghi M., Rikhtehgar M.H., Rezaei Kanavi M., Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. 2021 Apr 10 doi: 10.1177/11206721211009450. 11206721211009450. [Online ahead of print]
    1. Sargin F., Akbulut M., Karaduman S., Sungurtekin H. Severe rhinocerebral mucormycosis case developed after COVID 19. J Bacteriol Parasitol. 2021;12:386.
    1. Waizel-Haiat S., Guerrero-Paz J.A., Sanchez-Hurtado L., et al. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus. 2021;13 e13163.
    1. Zurl C., Hoenigl M., Schulz E., et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel). 2021 Jan 27;7(2):88.
    1. Sugar A.M. Mucormycosis. Clin Infect Dis. 1992;14:S126–S129.
    1. Peterson K.L., Wang M., Canalis F.R., Abemayor E. Rhinocerebral mucormycosis: evolution of the disease and treatment options. Laryngoscope. 1997;107:855–862.
    1. Smith H.W., Kirchner J.A. Cerebral mucor-mycosis: a report of 3 cases. Arch Otolaryngol. 1950;68:715–726.
    1. Prakash H., Ghosh A.K., Rudramurthy S.M., et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57:395–402.
    1. Patel A., Kaur H., Xess I., et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7) 944.e9-944.e15.
    1. Bala K., Chander J., Handa U., et al. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol. 2015 Apr;53(3):248–257.
    1. John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021 Apr 15;7(4):298.
    1. Baldin C., Ibrahim A.S. Molecular mechanisms of mucormycosis -The bitter and the sweet. PLoS Pathog. 2017;13(8) e1006408.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다